SpyGlass Pharma to Participate in the Jefferies Biotech on the Beach Summit

Rhea-AI Summary

SpyGlass Pharma (Nasdaq: SGP) said its executive management team will host one-on-one meetings at the Jefferies Biotech on the Bay Summit in Miami Beach, Florida on Wednesday, March 11, 2026.

The meetings are management-led 1x1 investor sessions during the conference, offering direct Q&A opportunities.

News Market Reaction – SGP

-0.26%

-0.26% Session close to close

In the Mar 4 session, SGP declined 0.26%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement simply notes SpyGlass Pharma’s plan for executive 1x1 meetings at the Jefferies Bi...

Analysis

This announcement simply notes SpyGlass Pharma’s plan for executive 1x1 meetings at the Jefferies Biotech on the Bay Summit on March 11, 2026. It does not introduce new clinical or financial data. In the short time since its IPO, the company raised $172.5 million in gross proceeds at $16.00 per share and attracted sizable institutional holders. Investors may watch future updates on pipeline progress, post‑IPO execution, and additional regulatory or financing developments.

Key Figures

Summit date: March 11, 2026

1 metrics

Summit date March 11, 2026 Jefferies Biotech on the Bay Summit meetings

Historical Context

1 past event · Latest: Feb 09 (Positive)

Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 09	IPO completion	Positive	+6.3%	Closed IPO at $16 per share with $172.5M gross proceeds and full over-allotment.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Limited history: the only prior tracked event was the IPO, which saw a positive price reaction.

Recent Company History

SpyGlass Pharma began trading on Nasdaq under ticker SGP in early February 2026 following its IPO, which priced at $16.00 per share and generated aggregate gross proceeds of $172.5 million. The IPO included 10,781,250 shares, with underwriters fully exercising their option for an additional 1,406,250 shares. That event saw a 6.3% positive reaction over the next 24 hours. Since then, filings have highlighted sizable positions by institutional investors and insiders. Today’s conference-participation news comes against this early post-IPO backdrop.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ALISO VIEJO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma”), a late-stage biopharmaceutical company, today announced that members of the executive management team will host 1x1 meetings at the Jefferies Biotech on the Bay Summit in Miami Beach, Florida on Wednesday, March 11, 2026.

About SpyGlass Pharma

SpyGlass Pharma is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company’s mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation.

The SpyGlass Pharma platform, a novel, non-bioerodible drug delivery technology, is designed to be used with various well-established, approved medicines, including bimatoprost and other small molecules, providing flexibility to potentially treat a range of conditions in the front and back of the eye.

The company was founded in 2019 by Malik Y. Kahook, M.D. and Glenn Sussman to solve the lack of ophthalmic innovations that capitalize on durable treatment options. The SpyGlass Pharma platform was originally developed in the Sue Anschutz-Rodgers Eye Center at the University of Colorado Anschutz School of Medicine.

Media Contact:
Nami Surendranath
+1 (402) 507-6757
nsurendranath@dnacommunications.com

Investor Contact:
Ami Bavishi or Nick Colangelo
Gilmartin Group LLC
investors@spyglasspharma.com

FAQ

What is SpyGlass Pharma announcing for March 11, 2026 (SGP)?

SpyGlass Pharma will host one-on-one meetings with its executive management team on March 11, 2026. According to SpyGlass Pharma, these 1x1 sessions occur during the Jefferies Biotech on the Bay Summit in Miami Beach to provide direct investor engagement.

Where will SpyGlass Pharma (SGP) meet investors on March 11, 2026?

The meetings will take place in Miami Beach, Florida at the Jefferies Biotech on the Bay Summit on March 11, 2026. According to SpyGlass Pharma, executive management will host scheduled 1x1 investor meetings during the event.

Who from SpyGlass Pharma (SGP) will attend the Jefferies Biotech on the Bay Summit?

Members of SpyGlass Pharma's executive management team will attend and host one-on-one meetings at the summit. According to SpyGlass Pharma, company executives will lead the 1x1 sessions on March 11, 2026 to engage with investors.

Can investors request meetings with SpyGlass Pharma (SGP) at the March 11 event?

Investors can request one-on-one meetings with SpyGlass Pharma's executives at the summit, subject to scheduling. According to SpyGlass Pharma, the company will host 1x1 sessions at the Jefferies Biotech on the Bay Summit on March 11, 2026.

What topics will SpyGlass Pharma (SGP) cover in its Jefferies summit 1x1 meetings?

The company will offer direct Q&A and corporate updates in individual meetings with management at the summit. According to SpyGlass Pharma, the 1x1 sessions on March 11, 2026 are intended for investor dialogue and business discussion.